Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care
Key Highlights
- ➤79.1% of new ZUNVEYL (ACOG) residents reached therapeutic dose versus 37.3% on generic AChEIs
- ➤80.7% of previously treated ZUNVEYL (ACOG) residents reached therapeutic dose versus 54.0% on generics
- ➤ZUNVEYL (ACOG) residents saw net decreases across all eight medication classes
- ➤Generic AChEI residents saw net increases across all eight medication classes
- ➤CONVERGE analysis used long-term care medication data through June 30, 2026
Expert Statements
Michael McFadden, Chief Executive Officer of Alpha Cognition
“We are encouraged by the CONVERGE findings across these first two measures: therapeutic dosing and changes in concomitant medication use.”
Michael McFadden, Chief Executive Officer of Alpha Cognition
“The ability to reach a therapeutic dose is an important real-world indicator of successful treatment utilization, and understanding changes in medication burden is particularly relevant in long-term care, where polypharmacy is an important consideration.”
Michael McFadden, Chief Executive Officer of Alpha Cognition
“These initial findings are encouraging, and we look forward to analyzing additional measures as the CONVERGE dataset continues to grow.”
Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care
Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company") today announced initial results from CONVERGE, an ongoing retrospective real-world evidence evaluation using longitudinal long-term care medication-administration data. As part of the ongoing CONVERGE evidence-generation program, this analysis focused on 180-day titration and concomitant medication patterns among residents receiving ZUNVEYL (benzgalantamine), donepezil, galantamine or rivastigmine. These measures provide insight into how treatment is used in real-world long-term care settings, including whether residents reach therapeutic dosing and how their broader medication regimens change over time. The analysis included both residents who had not previously received an AChEI (acetylcholinesterase inhibitor) and residents who switched from another AChEI therapy.
Get started
Create a free account to read the full story.